TGTX · NASDAQ
TG Therapeutics (TGTX) Stock Price & Fundamentals
TG Therapeutics (TGTX) closed at $213.14 on Oct 9, 2026, up 1.31% from the previous close of $210.38.
Share price, past year
1Y +19.03%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $213.14 |
| Sep 30, 2026 | $206.49 |
| Aug 31, 2026 | $193.15 |
| Jul 31, 2026 | $185.21 |
| Jun 30, 2026 | $179.68 |
| May 29, 2026 | $176.33 |
| Apr 30, 2026 | $174.36 |
| Mar 31, 2026 | $172.27 |
| Feb 27, 2026 | $172.85 |
| Jan 30, 2026 | $176.39 |
| Dec 31, 2025 | $177.99 |
| Nov 28, 2025 | $174.62 |
| Oct 31, 2025 | $168.29 |
Key statistics
- Market cap
- $32.63B
- P/E (TTM)
- 77.8
- EPS (TTM)
- $2.74
- Revenue (TTM)
- $799.54M
- Net income (TTM)
- $441.49M
- Shares outstanding
- 153.1M
- Dividend yield
- —
- 52-week range
- $167.11 – $213.14
TG Therapeutics's market cap is $32.63B, based on a share price of $213.14 and 153.1M shares outstanding as of Jun 30, 2026.
Financials
TG Therapeutics reported revenue of $616.29M for fiscal 2025, up 87.32% from fiscal 2024.
TG Therapeutics earned net income of $447.18M in fiscal 2025, a net margin of 72.6%.
Fiscal 2025 revenue was the highest in the 10 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $616.29M | +87.3% | $447.18M | 72.6% | $2.77 | −$24.99M |
| FY2024ended Dec 31, 2024 | $329.00M | +40.8% | $23.38M | 7.1% | $0.15 | −$40.56M |
| FY2023ended Dec 31, 2023 | $233.66M | +8,290.0% | $12.67M | 5.4% | $0.09 | −$31.41M |
| FY2022ended Dec 31, 2022 | $2.79M | −58.4% | −$223.81M | −8,036.3% | −$1.65 | −$176.18M |
| FY2021ended Dec 31, 2021 | $6.69M | +4,300.7% | −$348.10M | −5,204.1% | −$2.63 | −$296.04M |
| FY2020ended Dec 31, 2020 | $152.00K | 0.0% | — | — | −$2.42 | −$214.86M |
| FY2019ended Dec 31, 2019 | $152.00K | 0.0% | — | — | −$1.96 | −$132.94M |
| FY2018ended Dec 31, 2018 | $152.00K | 0.0% | — | — | −$2.30 | −$129.02M |
| FY2017ended Dec 31, 2017 | $152.00K | 0.0% | — | — | −$1.91 | −$93.76M |
| FY2016ended Dec 31, 2016 | $152.00K | — | — | — | −$1.60 | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $240.34M | $7.78M | $0.05 |
| Q1 FY2026ended Mar 31, 2026 | $204.92M | $19.78M | $0.12 |
| Q4 FY2025ended Dec 31, 2025 | $192.57M | $23.04M | $0.14 |
| Q3 FY2025ended Sep 30, 2025 | $161.71M | $390.90M | $2.43 |
| Q2 FY2025ended Jun 30, 2025 | $141.15M | $28.19M | $0.17 |
| Q1 FY2025ended Mar 31, 2025 | $120.86M | $5.06M | $0.03 |
| Q4 FY2024ended Dec 31, 2024 | $108.19M | $23.33M | $0.16 |
| Q3 FY2024ended Sep 30, 2024 | $83.88M | $3.88M | $0.02 |
Company profile
- Name
- TG Therapeutics, Inc.
- Ticker
- TGTX
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 2 Gansevoort Street, 9th Floor, New York, NY 10014
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001001316
Recent SEC filings
- Aug 5, 2026
- Aug 3, 2026
- Jun 12, 2026
- Jun 3, 2026
- May 27, 2026
- May 6, 2026
- May 6, 2026
- Mar 20, 2026
Frequently asked questions
What is TG Therapeutics's stock price?
TG Therapeutics (TGTX) closed at $213.14 on Oct 9, 2026, up 1.31% from the previous close of $210.38.
What is TG Therapeutics's market cap?
TG Therapeutics's market cap is $32.63B, based on a share price of $213.14 and 153.1M shares outstanding as of Jun 30, 2026.
How much revenue does TG Therapeutics make?
TG Therapeutics reported revenue of $616.29M for fiscal 2025, up 87.32% from fiscal 2024.
What is TGTX's P/E ratio?
TG Therapeutics's price-to-earnings ratio is 77.8, based on trailing twelve-month diluted EPS of $2.74.
Does TG Therapeutics pay a dividend?
TG Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from TG Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures